🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 89357L501 (prev. 89357L204 )
- Market Cap
- Micro Cap
- IPO
- 7/9/2021 · $4.00/share
Business: TransCode Therapeutics, Inc. is an emerging RNA oncology company committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics. TransCode’s proprietary platform, TTX, repurposes an iron oxide nanoparticle that has been extensively used for imaging to solve for RNA delivery in oncology.
Notes: May 19, 2023 -- TransCode Therapeutics, Inc. (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split (the “Reverse Split”) of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”), as of 4:05 p.m. Eastern Time on May 22, 2023 (the “Effective Time”). Beginning with the opening of trading on May 23, 2023, the Company’s Common Stock is expected to trade on the Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 89357L204.
Company Contact
- CEO
- Thomas A. Fitzgerald
- CFO
- Thomas A. Fitzgerald
- Headquarters
- 6 Liberty Square, #2382, Boston, MA 02109
- Phone
- 857-837-3099
- Investor Relations
- Josh Rappaport, Stern IR · 212-362-1200 · josh.rappaport@sternir.com